Back to News
Market Impact: 0.42
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Biofrontera's Ameluz, used with the RhodoLED lamp, became the first and only photodynamic therapy approved in the United States to treat a skin cancer. The approval opens an additional growth opportunity for Biofrontera's photodynamic-therapy platform and strengthens its differentiation in the U.S. dermatology market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
BFRI0.82
More News
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Microsoft’s strong quarter backs up its stock rebound. Here's our new price target
- Aker BP Q3 profit tops forecast on $870 million writedown reversal
- As Waymo expands overseas, it remains a niche cash-burning business
- Google struggling to make AI Mode searches pay